RenovoRx (NASDAQ:RNXT) Announces Quarterly Earnings Results, Hits Estimates

RenovoRx (NASDAQ:RNXT) posted its quarterly earnings data on Thursday. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08), FiscalAI reports. RenovoRx had a negative net margin of 994.48% and a negative return on equity of 119.77%. The firm had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.47 million.

Here are the key takeaways from RenovoRx’s conference call:

• RenovoRx reported record Q1 2026 revenue of $563,000, up 136% sequentially from Q4 2025 and more than half of full-year 2025 revenue, signaling that its commercial model is starting to scale.
• The company said it now has 16 active commercial cancer centers as of May 2026, up from 8 at year-end 2025, with 32 more centers in the pipeline and a target of 36 centers by year-end.
• Management reiterated full-year 2026 revenue guidance of $3 million to $4 million and said second-quarter revenue is tracking above Q1, which they believe keeps them on plan.
• The TIGeR-PaC Phase III trial is nearing enrollment completion, with 106 of 114 patients randomized and enrollment expected to close in early June, while final data remains expected in mid-to-late 2027.
• RenovoRx completed an oversubscribed $10 million private placement and ended Q1 with $12.4 million in cash, giving it runway into the second half of 2027 as it works toward cash flow breakeven.

RenovoRx Stock Performance

RNXT traded down $0.04 during trading on Friday, reaching $0.82. 647,593 shares of the company’s stock were exchanged, compared to its average volume of 328,149. The company’s fifty day moving average price is $0.94 and its 200-day moving average price is $0.94. RenovoRx has a fifty-two week low of $0.70 and a fifty-two week high of $1.45. The firm has a market capitalization of $36.94 million, a PE ratio of -2.56 and a beta of 1.00.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. JonesTrading upgraded shares of RenovoRx to a “strong-buy” rating in a research report on Thursday, January 29th. HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of RenovoRx in a research report on Wednesday, April 8th. Ascendiant Capital Markets boosted their price objective on shares of RenovoRx from $13.00 to $13.50 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Finally, Wall Street Zen cut shares of RenovoRx from a “hold” rating to a “strong sell” rating in a research report on Saturday, April 4th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, RenovoRx has an average rating of “Moderate Buy” and an average target price of $8.25.

Institutional Trading of RenovoRx

A number of institutional investors have recently bought and sold shares of the business. XTX Topco Ltd grew its holdings in RenovoRx by 58.6% during the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock worth $42,000 after acquiring an additional 18,525 shares during the period. Bleichroeder LP grew its holdings in RenovoRx by 11.4% during the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock worth $504,000 after acquiring an additional 61,379 shares during the period. Wealthspire Advisors LLC acquired a new stake in RenovoRx during the 4th quarter worth $212,000. Citadel Advisors LLC acquired a new stake in RenovoRx during the 3rd quarter worth $154,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in RenovoRx during the 2nd quarter worth $98,000. Institutional investors and hedge funds own 3.10% of the company’s stock.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.